Iredale, Philip
- Cerevel Therapeutics, LLC (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #2,227
- Early Career
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2021 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$2.7M
Full award amounts, FY2023
Award Records
1
Records listing this PI
Award-Linked Rank
#2,227
By linked amount among FY2023 PIs
Earliest Year Loaded
2021
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Iredale, Philip as a PI. Multi-PI records show the full award amount for context.
- 4UH3DA052166-02UH3Contact PICVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse$2.7Maward amount
Award organization
Organizations that administered FY2023 awards listing Iredale, Philip as a PI.
FY2023 award administered by Cerevel Therapeutics, LLC (MA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2021First NIH AwardCerevel Therapeutics, LLC
- 2021$500K Cumulative Funding
- 2021$1M Cumulative Funding
- 2021$2M Cumulative Funding
- 2021$5M Cumulative Funding
- 2021Entered Top 50% NationallyRanked #617
- 2021Entered Top 25% NationallyRanked #617
- 2021Entered Top 10% NationallyRanked #617
- 2021Entered Top 5% NationallyRanked #617